Lonza Expands its TheraPEAK ® Product Portfolio with the Addition of AmpliCell ® Cytokine Range and TheraPEAK ® 293-GT ® Medium

Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced the launch of TheraPEAK ® AmpliCell ® Cytokines and TheraPEAK ® 293-GT ® Medium to expand its GMP solutions for cell and gene therapy.

Cytokines represent a critical component in cell therapy manufacturing, supporting the expansion and maintenance of living cells. TheraPEAK ® AmpliCell ® Cytokines enable the reliable expansion, activation, and differentiation of immune cells. Produced in a mammalian expression system and engineered for high biological activity, these cytokines feature proper folding and glycosylation, delivering native-like structure and function that bacterial systems cannot match. This ensures superior biological relevance, batch-to-batch consistency, and greater predictability in sensitive and translational applications, both in research and GMP set-ups.

TheraPEAK ® 293-GT ® Medium is a chemically defined, animal–origin–free system optimized for adeno-associated virus (AAV) production in suspension HEK293 cells, providing a reliable, scalable option for advancing gene therapy programs. Unlike off-the-shelf viral production kits that may lack flexibility, the 293-GT ® System (growth medium plus supplement) is a drop-in-ready solution engineered to integrate seamlessly with existing workflows. The media is compatible with commercially available transfection reagents and AAV enhancers, delivers strong AAV titers, and supports high full-to-empty capsid ratios.

TheraPEAK ® Products have been used in FDA-approved therapies and more than 130 clinical trials across the globe. The newly-added solutions provide researchers and manufacturers with high-performance, scalable, and regulatory-ready solutions that streamline cell and gene therapy workflows from discovery through clinical development.

Mike Goetter, Head of Bioscience, Specialized Modalities, Lonza, said: “The introduction of AmpliCell ® Cytokines and the 293-GT ® Medium to our TheraPEAK ® Range greatly enhances our offering for cell and gene therapy customers, providing them with reliable solutions to support their drug development efforts.”

Additional Information
To learn more about Lonza’s TheraPEAK® products, visit: https://bioscience.lonza.com/lonza_bs/GB/en/consistency-you-can-count-on-therapeak-amplicell-cytokines Lonza

Contact Details
media@lonza.com